Regencell CEO Yat-Gai Au has created an organization that is about more than profits -- it's about changing lives. His aim is to change the way patients are treated
Human genius grows from humble origins.
Yat-Gai Au developed Regencell Bioscience to help more people benefit from natural and holistic medicines, with the objective of ensuring that everyone has equitable access to such therapy for many years to come.
Several individuals have made significant contributions to RGC's overall performance during the previous few years. Dr. Chao (Chief Medical Officer) and James Chung (Chief Operating Officer), who joined Regencell in 2015 and 2019, respectively, were motivated by their own experiences with TCM and the significant improvements they saw in ADHD and ASD patients.
"For our organisation to remain loyal to what we believe in and continue to move in the correct path, we must surround ourselves with the appropriate individuals who share our values and interests. Our staff creates plans and supervises scientific testing to verify that our services and products are effective, safe, and beneficial "Yat-Gai concurs.
The organisation has evolved into more than merely a research and development institution for neurocognitive diseases and degenerations. "It is opening the path for exceptional advancements in TCM to become commonplace. Why should these ground-breaking therapies be limited to a restricted set of individuals or communities?"
The results of a recent clinical trial, the EARTH Trial, revealed that RGC-COV19TM is an effective solution for the relief and eradication of COVID-19 symptoms within 6 days. As a result, the chances of hospitalisation and mortality are reduced. TCM and traditional medicine have been demonstrated to be successful in a hyper-modern, tech-driven environment through rigorous experiments.
Keeping it intimate and close
Although RGC's clinical trials will still need to be peer-reviewed in the coming months, there is significant market interest because the firm has created a reputation for its research and development (R&D) in the field of alternative medicine.
"We are a company that seeks to make a difference wherever feasible, and while our R&D may be confined to a few sectors of interest, we will be able to widen our perspectives to more complicated therapies over time," Yat-Gai quickly remarks.
Regencell received net funds of $22.7 million from its IPO, investments that aided the company's access to the tools and resources required to expedite clinical research.
Yat-Gai has found that after the company became public, short and distorting groups or people have begun to impact their stock price and mood. "Enterprises like ours are not given the opportunity to establish themselves because the offenders are pushing down the value of smaller companies, leading the market and general public to lose faith. This harms our firm, notably the patients, some of whom are yearning for a solution "he stated.
Yat-Gai was able to acquire over $5.9 million in regular firm shares to assist reduce the detrimental consequences of such short-term strategies. Yat-Gai Au currently holds an 81% ownership in the firm. Other owners possess around 19% of the remaining shares.
"To date, I have invested millions of dollars of my personal funds on RGC stock. My most recent acquisition was $886,000 in RGC shares at an average price of US$39.48, increasing my shareholdings by 0.2%. I believe in the firm and its future, and I aim to continue putting my money where my mouth is by increasing my shareholdings."
Because majority ownership is kept within the firm, often known as 'Insider Ownership,' it allows them to have greater influence over crucial decision-making concerns, which can assist accelerate the company's overall development goals.
"The decision to continually acquire RGC shares over the last several months is to support and ensure the company's promise may be realised for years to come. We've invested a lot of time, energy, and money in Regencell, and we're fully aware of the potential difference it can make in the area of alternative medicine. I feel that if I lead the way, our organisation will be able to reach the goals we've set for ourselves in the next years."
Long-term transactions not only provide the firm more control over important decision-making, but also allow them to increase investor sentiment.
https://www.ibtimes.com/regencell-ceo-shares-...ed-3600337
Human genius grows from humble origins.
Yat-Gai Au developed Regencell Bioscience to help more people benefit from natural and holistic medicines, with the objective of ensuring that everyone has equitable access to such therapy for many years to come.
Several individuals have made significant contributions to RGC's overall performance during the previous few years. Dr. Chao (Chief Medical Officer) and James Chung (Chief Operating Officer), who joined Regencell in 2015 and 2019, respectively, were motivated by their own experiences with TCM and the significant improvements they saw in ADHD and ASD patients.
"For our organisation to remain loyal to what we believe in and continue to move in the correct path, we must surround ourselves with the appropriate individuals who share our values and interests. Our staff creates plans and supervises scientific testing to verify that our services and products are effective, safe, and beneficial "Yat-Gai concurs.
The organisation has evolved into more than merely a research and development institution for neurocognitive diseases and degenerations. "It is opening the path for exceptional advancements in TCM to become commonplace. Why should these ground-breaking therapies be limited to a restricted set of individuals or communities?"
The results of a recent clinical trial, the EARTH Trial, revealed that RGC-COV19TM is an effective solution for the relief and eradication of COVID-19 symptoms within 6 days. As a result, the chances of hospitalisation and mortality are reduced. TCM and traditional medicine have been demonstrated to be successful in a hyper-modern, tech-driven environment through rigorous experiments.
Keeping it intimate and close
Although RGC's clinical trials will still need to be peer-reviewed in the coming months, there is significant market interest because the firm has created a reputation for its research and development (R&D) in the field of alternative medicine.
"We are a company that seeks to make a difference wherever feasible, and while our R&D may be confined to a few sectors of interest, we will be able to widen our perspectives to more complicated therapies over time," Yat-Gai quickly remarks.
Regencell received net funds of $22.7 million from its IPO, investments that aided the company's access to the tools and resources required to expedite clinical research.
Yat-Gai has found that after the company became public, short and distorting groups or people have begun to impact their stock price and mood. "Enterprises like ours are not given the opportunity to establish themselves because the offenders are pushing down the value of smaller companies, leading the market and general public to lose faith. This harms our firm, notably the patients, some of whom are yearning for a solution "he stated.
Yat-Gai was able to acquire over $5.9 million in regular firm shares to assist reduce the detrimental consequences of such short-term strategies. Yat-Gai Au currently holds an 81% ownership in the firm. Other owners possess around 19% of the remaining shares.
"To date, I have invested millions of dollars of my personal funds on RGC stock. My most recent acquisition was $886,000 in RGC shares at an average price of US$39.48, increasing my shareholdings by 0.2%. I believe in the firm and its future, and I aim to continue putting my money where my mouth is by increasing my shareholdings."
Because majority ownership is kept within the firm, often known as 'Insider Ownership,' it allows them to have greater influence over crucial decision-making concerns, which can assist accelerate the company's overall development goals.
"The decision to continually acquire RGC shares over the last several months is to support and ensure the company's promise may be realised for years to come. We've invested a lot of time, energy, and money in Regencell, and we're fully aware of the potential difference it can make in the area of alternative medicine. I feel that if I lead the way, our organisation will be able to reach the goals we've set for ourselves in the next years."
Long-term transactions not only provide the firm more control over important decision-making, but also allow them to increase investor sentiment.
https://www.ibtimes.com/regencell-ceo-shares-...ed-3600337
